A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 12 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 28 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.